UVA and UVB‐Induced 8‐Methoxypsoralen Photoadducts and a Novel Method for their Detection by Surface‐Enhanced Laser Desorption Ionization Time‐of‐Flight Mass Spectrometry (SELDI‐TOF MS)

Citations Over TimeTop 15% of 2013 papers

Abstract

UVA-activated psoralens are used to treat hyperproliferative skin conditions due to their ability to form DNA photoadducts, which impair cellular processes and may lead to cell death. Although UVA (320-400 nm) is more commonly used clinically, studies have shown that UVB (280-320 nm) activation of psoralen can also be effective. However, there has been no characterization of UVB-induced adduct formation in DNA alone. As psoralen derivatives have a greater extinction coefficient in the UVB region (11 800 cm(-1) M(-1) at 300 nm) compared with the UVA region (2016 cm(-1) M(-1) at 365 nm), a greater extent of adduct formation is expected. SELDI-TOF, a proteomic technique that combines chromatography with mass spectrometry, was used to detect photoadduct formation in an alternating A-T oligonucleotide. 8-Methoxypsoralen (8-MOP) and DNA solutions were irradiated with either UVA or UVB. An adduct peak was obtained with SELDI-TOF. For UVB-activated 8-MOP, the extent of adducts was three times greater than for UVA. HPLC ESI-MS analysis showed that UVB irradiation yielded high levels of 3,4-monoadducts (78% of total adducts). UVA was more effective than UVB at conversion of 4',5'-monoadducts to crosslinks (17% vs 4%, respectively). This report presents a method for comparing DNA binding efficiencies of interstrand crosslink inducing agents.

Related Papers

• → Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)(1997)662 cited
• → Unique Crosslinking Properties of Psoralen‐Conjugated Oligonucleotides Developed by Novel Psoralen N‐Hydroxysuccinimide Esters(2023)10 cited
• → Lenticular Psoralen Photoproducts and Cataracts of a PUVA-Treated Psoriatic Patient(1985)28 cited
• → Methoxsalen serum level variations in psoralen and ultraviolet-A (PUVA) therapy(1981)
• → Front Cover: Unique Crosslinking Properties of Psoralen‐Conjugated Oligonucleotides Developed by Novel Psoralen N‐Hydroxysuccinimide Esters (ChemBioChem 15/2023)(2023)